Use of advanced statistical techniques to predict all-cause mortality in the Systolic Blood Pressure Intervention Trial by Kostis, William et al.
Thomas Jefferson University 
Jefferson Digital Commons 
Department of Medicine Faculty Papers Department of Medicine 
9-19-2020 
Use of advanced statistical techniques to predict all-cause 
mortality in the Systolic Blood Pressure Intervention Trial 
William Kostis 
Rutgers Robert Wood Johnson Medical School 
Javier Cabrera 
Rutgers University 
Chun Pang Lin 
Rutgers Robert Wood Johnson Medical School 
John Kostis 
Rutgers Robert Wood Johnson Medical School 
Jennifer Wellings 
Thomas Jefferson University 
See next page for additional authors 
Follow this and additional works at: https://jdc.jefferson.edu/medfp 
 Part of the Cardiology Commons, and the Vital and Health Statistics Commons 
Let us know how access to this document benefits you 
Recommended Citation 
Kostis, William; Cabrera, Javier; Lin, Chun Pang; Kostis, John; Wellings, Jennifer; Zinonos, 
Stavros; Dobrzynski, Jeanne; and Blickstein, Daniel, "Use of advanced statistical techniques to 
predict all-cause mortality in the Systolic Blood Pressure Intervention Trial" (2020). Department 
of Medicine Faculty Papers. Paper 279. 
https://jdc.jefferson.edu/medfp/279 
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital 
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is 
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections 
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested 
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been 
accepted for inclusion in Department of Medicine Faculty Papers by an authorized administrator of the Jefferson 
Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu. 
Authors 
William Kostis, Javier Cabrera, Chun Pang Lin, John Kostis, Jennifer Wellings, Stavros Zinonos, Jeanne 
Dobrzynski, and Daniel Blickstein 
This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/medfp/279 
Research Paper
Use of advanced statistical techniques to predict all-cause mortality in the
Systolic Blood Pressure Intervention Trial
William J. Kostis a, Javier Cabrera b, Chun Pang Lin a, John B. Kostis a,*, Jennifer Wellings c,
Stavros Zinonos a, Jeanne M. Dobrzynski a, Daniel Blickstein a
a Cardiovascular Institute, Rutgers Robert Wood Johnson Medical School, New Brunswick, 08901, NJ, USA
b Department of Statistics, Rutgers University, Piscataway, 08854, NJ, USA
c Medicine, Thomas Jefferson University, Philadelphia, 19107, PA, USA






A B S T R A C T
Background: The Systolic Blood Pressure Intervention Trial (SPRINT) was conducted in patients with hypertension
and additional risk for cardiovascular disease who were randomized to the intensive blood pressure group tar-
geting systolic blood pressure (SBP) less than 120 mm Hg and to the standard group where the target was less
than 140 mm Hg. Analyses were done in the matched group of participants with the same gender, same age (2
years) and same SBP (3 mm Hg) at three months of treatment regardless of initial randomization to intensive or
standard group (shaded area in Figure 1).
Methods and results: During 3.26 years of follow-up, intensive group participants had 14.8 mm Hg lower SBP and
received on average one more (2.8 vs. 1.8) blood pressure lowering medications. This was associated with lower
all-cause mortality in the intensive treatment group (hazard ratio, 0.73; 95% CI, 0.60 to 0.90, p ¼ 0.003). The
effect on SBP was achieved at 3 months and remained unchanged thereafter. This paper addresses two questions
with respect to all-cause mortality in SPRINT in the matched set. 1) What is the effect of receiving more than one
drug on all-cause mortality. Conditional logistic regression for all-cause mortality with respect to number of drugs
indicated that during the 3.26 years of follow-up persons who received more than one drug were more likely to
die (coefficient ¼ 0.5039, OR ¼ 1.6552, p ¼ 0.0322) than patients who received one drug. 2) Was there a U curve
relationship between on treatment SBP and all-cause mortality? A U curve fitting a quadratic equation (parabola)
of SBP and all-cause death was observed. This was seen in the patients randomized to the standard target group in
unadjusted analyses as well as in analyses adjusted for demographics or all covariates (p < 0.001 for all). The U
curves in the combined group and the intensive treatment group were less pronounced.
Conclusion: SPRINT participants who were matched for gender, age, and SBP at 3 months, and received more than
one drug had higher all-cause mortality during the 3.26 years of follow-up. Those who were randomized to
standard treatment target had a U curve relationship between SBP at three months and all-cause mortality. The U
curves in the combined group and the intensive treatment group were less pronounced.
1. Introduction
Hypertension is the leading preventable cause of premature death
worldwide [1] and directly increases risk of cardiovascular mortality [2,
3]. Systolic blood pressure (SBP) is an independent risk predictor for
stroke, heart failure, and coronary events [4–6]. The Systolic Blood
Pressure Intervention Trial (SPRINT) showed that lowering systolic blood
pressure to a target of less than 120 mm Hg compared to 140 mm Hg
resulted in lower rates of mortality and nonfatal cardiovascular events
[3] as well as all-cause mortality. Other factors such as comorbidities,
demographics and visit to visit variability and low adherence may affect
mortality of patients with hypertension [7–10]. In SPRINT, patients were
randomized to a target SBP of 120 mm Hg or 140 mm Hg. Participants
were seen every month for the first three months and every month
thereafter. Dose adjustments were based on an average of three blood
pressure measurements during the office visit after the patient was seated
for 5 minutes when antihypertensive regimens were adjusted based on
the study group assignment. The primary composite outcome included
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myocardial infarction, acute coronary syndrome not resulting in
myocardial infarction, stroke, acute decompensated heart failure or
death from any cause. The outcome examined in this paper is death from
any cause.
The first objective of this paper was to examine whether SPRINT
participants who required more than one drug to achieve a given SBP at
three months had higher mortality than those requiring only one drug.
The second objective was to examine whether there were U curves in
the relationship of SBP at three months and death from any cause. A U
curve is a graphical representation of a relationship between risk and
outcome where, if the risk factor is at an optimum level the likelihood of
an adverse outcome, in this case death, is lowest and increases on either
side of the nadir. It was first reported by Stewart in 1979 who in a survey
of 169 patients with hypertension observed that the relative risk of
myocardial infarction in patients with DBP below 90 mm Hg was about 5
times as high than in patients with DBP 100–109 mmHg (p< 0.01) [11].
Since the introduction of the concept of a physiological optimum, U or J
curve relationships have been observed in risk-outcome models of
alcohol with all-cause mortality [12], systolic and diastolic blood pres-
sure with cardiovascular outcomes [13,14] and serum potassium with
mortality in chronic heart failure [15].
The purpose of this study is to report on whether receiving more than
one drug to achieve the same blood pressure at follow up is associated
with increased all-cause mortality in SPRINT and to examine whether U
curve relationships exist between on treatment and all-cause mortality.
2. Methods
SPRINT was a randomized, controlled, open-label trial, in 102
participating study locations on patients who were at least 50 years old,
had SBP of 130–180 mm Hg, and had an increased risk of cardiovascular
events. Increased cardiovascular risk was defined by one or more of the
following: clinical or subclinical cardiovascular disease other than stroke,
chronic kidney disease with eGFR of 20 to less than 60 ml/min per 1.73
m2 BSA 10-year risk of cardiovascular disease of 15% or greater on the
basis of the Framingham risk score and age of 75 years or older. Patients
with diabetes, prior stroke, congestive heart failure with symptoms or
ejection fraction less than 35%, proteinuria over 1 g per day, or problems
with medication adherence were excluded. Demographic data were
collected at baseline and clinical and laboratory data were collected at
baseline and subsequently every 3 months.
Participants were assigned to a standard-treatment group with blood
pressure target of less than 140 mm Hg or an intensive-treatment group
with a target of less than 120 mm Hg. This resulted in three subsets of
participants as shown in Fig. 1: those randomized to the intensive SBP
target of less than 120 mm Hg (left), those randomized to the standard
SBP target of less than 140 mm Hg (right) and the intersection or
matched group that included participants who had the same gender,
same age (2 years) and same SBP (3 mm Hg) at three months of
treatment regardless of randomization to intensive or standard group.
Among the 8919 SPRINT patients with complete data, the matched group
included 5814 patients (2907 pairs) who achieved similar SBP (3 mm
Hg) at 3 months of treatment regardless of randomization to intensive or
standard treatment. At 1 year, the mean SBP was 121.4 mm Hg in the
intensive treatment group and 136.2 mm Hg in the standard treatment
group. The effect on SBP was achieved at 3 months and remained un-
changed thereafter. All-cause mortality, the focus of this paper, was
significantly lower in the intensive treatment group (hazard ratio, 0.73;
95% CI, 0.60 to 0.90; p ¼ 0.003). This analysis was performed by the
SPRINT study investigators.
Statistical analyses pertaining to J and U curves were performed by a
method reported by Amaratunga and Cabrera in 2015. They examined
the presence of linear trends versus nonlinear trends such as U curves or J
curves by fitting incrementally linear, quadratic and tricubic equations to
the data. U curves or quadratic curves are second order polynomials
where both branches are symmetric. On the other hand, J curves are
cubic splines with one knot at the median of the X variable [17]. J curves
are suitable when the relationship is not symmetric. The fitting method
used for these relationships is incremental, starting with a linear fit then
adding a quadratic term and then adding the cubic spline term also called
tricubic. To decide between a U curve and a J curve we compared the
p-value of the U curve to the p-value of the J curve. If the p-value of the U
curve was higher than the p-value of the J curve, the relationship is
quadratic or U shaped. If the opposite is true, the relationship is J shaped.
The outputs of these equations include confidence intervals and p-values
[16].
This method works for linear regression models, logistic regression
models and Cox proportional hazard models. The response (Y) could be a
numeric response (SBP) or binary (dead or alive) or time to event (time to
death). In the logistic model the response gets translated to a response
such as logit(Prob(Dead)) (where logit(p)¼ log(p/(1-p))), in the survivals
model the response is the log(hazard ratio).
The U-shaped model is given by the equation
Response ¼ linear þ quadratic term, The J-shaped model is
Resp ¼ linear þ quadratic þ tri-cubic.
The tri-cubic term is written as ðSBP SBP0Þ3þ, which means equals to
ðSBP SBP0Þ3 if SBP > SBP0 and 0 if SBP  SBP0. We chose SBP0 as the
median SBP.
We tested the difference between the quadratic and cubic models by
using a likelihood ratio chi-square test.
This paper addresses two questions with respect to all-cause mortality
in the matched group of SPRINT participants. 1) What was the effect of
receiving more than one drug on all-cause mortality. 2) Was there a U
curve relationship between on treatment SBP and all-cause mortality in
the matched, standard, and intensive target groups.
This paper aims to answer 2 questions with respect to all-cause
mortality:
1. What is the effect of receivingmore than one drug to achieve the same
SBP at three months on all-cause mortality compared to those using
one drug in SPRINT? Conditional logistic regression, a standard
modeling procedure for matched pairs [18], for all-cause mortality
with respect to number of drugs was performed. The observations
were stratified by one-to-one matched pairs, as explained earlier in
this section, and the number of drugs was coded by an indicator
Fig. 1. Distribution on the left (red) pertains to patients randomized to the
intensive target group. Distribution on the right (green) pertains to patients
randomized to the standard target group. Shaded area in black represents pa-
tients who had the same gender, systolic blood pressure 3 mm Hg and age 2
years, at three months regardless of whether they were initially randomized to
the intensive target group or to the standard target group. . (For interpretation of
the references to colour in this figure legend, the reader is referred to the Web
version of this article.)
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variable taking value 1 for more than one drug vs value 0 for one or no
drugs.
2. Are there U curve relationships between on treatment SBP and all-
cause mortality in the standard and intensive groups of SPRINT?
Following the procedure for detecting U and J curves outlined in the
paragraph above, we investigated the presence and configuration of
U-curves in the matched set, the standard SBP target group and the
intensive target group.
3. Results
During the 3.26 years of follow-up, intensive group participants had
14.8 mm Hg lower SBP and received on average one more (2.8 vs. 1.8,
mean: 2.631, SD 1.029 vs. 1.826, SD 1.052) blood pressure lowering
medications. These data are consonant with current literature on these
medications. This was associated with lower all-cause mortality in the
intensive treatment group (hazard ratio, 0.73; 95% CI, 0.60 to 0.90,
p ¼ 0.003). These analyses were performed by the SPRINT study in-
vestigators. There were only 489 patients who at randomization were on
monotherapy and who remained on monotherapy until the end of the
third month visit. This analysis was performed by the investigators of this
paper. In these patients, the days from randomization were mean 96
days, median 93 days, lower quartile 91 days, higher quartile 101 days,
minimum 76 days and maximum 139 days. Four patients died (two from
cardiovascular causes) before the end of the three months. The times of
death were at 34, 52, 70 and 88 days. This did not allow formal survival
analysis in this subset. This analysis was performed by the investigators
of this paper. Cardiovascular mortality was not significantly higher in
patients receiving more than one drug compared to those who received
only one drug and the time was at three months (OR ¼ 2.4, 95% CI
0.8455-6.812, p ¼ 0.1). The characteristics of the matched group are
reported in Table 1.
This analysis was performed by investigators of the present paper
who used data from SPRINT. In the matched group, persons who received
more than one drug were more likely to die (coefficient ¼ 0.5039,
OR ¼ 1.6552, 95% CI 1.044-2.624, p ¼ 0.032). The proportion of sub-
jects who died was correlated to the baseline DBP, SBP and pulse pres-
sure. In the standard treatment group, a U curve of SBP and all-cause
death was observed in unadjusted analyses as well as for analyses
adjusted for demographics or all covariates (p< 0.001 for all (Fig. 2). The
U curves in the combined group (Fig. 3) and the intensive treatment
group were less pronounced (p ¼ 0.26 and 0.43 respectively). Patients
with low SBP were more likely to be Hispanic, with history of cardio-
vascular disease, and to take a statin. Patients with high SBP were more
likely to be black, have higher Framingham risk score and higher LDL. In
the matched group the U curve was evident but of borderline statistical
significance (Fig. 3 p ¼ 0.26) and a statistically significant U curve effect
was not observed in the intensive treatment group.
4. Discussion
In this study of SPRINT participants who had the same blood pressure
at 3 months of therapy, persons who received more than one drug were
more likely to die. This finding is consistent with the fact that the Fra-
mingham Risk Score assigns a point to those receiving antihypertensive
therapy. Administration of more than one drug may lead to more blood
pressure variability throughout the day as well as lower adherence an
important cause of uncontrolled or resistant hypertension.
A J curve of SBP and all-cause death was observed in unadjusted
analyses as well as for analyses adjusted for demographics or all cova-
riates in the standard treatment group (p < 0.001 for all, (Fig. 2) while in
the matched group the U curve was evident but of borderline statistical
significance (Fig. 3, p ¼ 0.26) and a statistically significant U curve was
not observed in the intensive treatment group.
Limitations of this study include that it is a post hoc analysis of data
collected in SPRINT that did not include patients with diabetes, patients
with prior stroke, those residing in nursing homes or assisted-living fa-
cilities. An additional limitation is that precise information on previous
(prior to randomization) exposure is not available in the SPRINT data-
base. However, the trial was randomized, included a large sample size
with participants of diverse ages, demographics and comorbidities. Also,
Table 1










Overall 68.1  9.3 68.1  9.4 0.9944
Among those  75 yr of age 79.7  3.8 79.6  3.8 0.9026
Male gender – no. (%)a 1897 (65.3) 1897 (65.3) 1
SBP at 3 months — mm Hga 128.9  12.6 129.4  12.6 0.0979
DBP at 3 months — mm Hg 71.5  10.8 72.8  10.9 <0.0001
Requiring >1 drug at 3 months
– no. (%)
2597 (89.3) 1622 (55.8) <0.0001
Criterion for increased cardiovascular risk — no. (%)
Age 75 yr 855 (29.4) 857 (29.5) 0.977
Chronic kidney disease 839 (28.9) 815 (28) 0.5038
Cardiovascular disease 567 (19.5) 572 (19.7) 0.8948
Clinical 465 (16) 488 (16.8) 0.4358




1852 (64) 1774 (61.3) 0.0430
Race or ethnic group 0.3803
Non-Hispanic black 860 (29.6) 874 (30.1)
Hispanic 284 (9.8) 279 (9.6)
Non-Hispanic white 1698 (58.4) 1707 (58.7)
Other 65 (2.2) 47 (1.6)
Black race 904 (31.1) 917 (31.5) 0.7344
Baseline SBP — mm Hg 141  15.8 138.7  15 <0.0001
Baseline DBP — mm Hg 78.3  12.2 77.7  11.8 0.05622
Serum creatinine — mg/dl 1.08  0.34 1.08  0.34 0.737
Estimated GFR — ml/min/1.73 m2
Among all participants 71.8  20.9 71.5  20.3 0.5238
Among those with estimated
GFR 60 ml/min/1.73 m2
81.6  15.7 80.8  15.1 0.1067
Among those with estimated
GFR <60 ml/min/1.73 m2
47.8  9.3 47.6  9.5 0.6317
Ratio of urinary albumin (mg)
to creatinine (g)
44.5  173.8 38.3  145.6 0.1457
Fasting total cholesterol —
mg/dl
189.9  41 189.5  40.9 0.6661
Fasting HDL cholesterol —
mg/dl
53  14.6 52.8  14.3 0.4324
Fasting total triglycerides —
mg/dl
124.4  88.1 125.6  80.5 0.57
Fasting plasma glucose — mg/
dl
99  13.6 98.7  12.8 0.4009





Aspirin use— no./total no. (%) 1508/2901 (52) 1494/2902
(51.5)
0.7225
Smoking status — no. (%) 0.2449
Never smoked 1279 (44) 1281 (44.1)
Former smoker 1226 (42.2) 1273 (43.8)
Current smoker 399 (13.7) 351 (12.1)




20.5  10.9 19.8  10.4 0.0083
Body-mass index 29.7  5.6 29.9  5.8 0.1582
Antihypertensive agents —
no./patient
1.8  1 1.8  1 0.5367
Not using antihypertensive
agents — no. (%)
265 (9.1) 274 (9.4) 0.7175
The p value is obtained from a two-sample t-test (for continuous variables) or a
chi-square test (for categorical variables).
a Variables used for matching.
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it proved an all-cause mortality difference between the two randomized
groups.
Our study implies that caution is needed prior to prescribing and
administering more than one antihypertensive medication and perhaps
when desired blood pressure control is not achieved to make sure that the
maximum dose on the first medication is given and to be vigilant
regarding elderly patients and patients with comorbidities or other
characteristics that put them on the left side of the U curve [17,18].
Adherence to medications is important, as more blood pressure medi-
cations may be added unnecessarily with nonadherence, increasing the
burden of unwanted side effects. Polypharmacy or inappropriate dosing
may cause cognitive and mental status changes especially in the elderly,
due to decreased cerebral perfusion, along with electrolyte imbalance
and other cardiovascular events.
It is not clear why a statistically significant U curve relationship was
observed in the standard treatment group, but not in the intensive care
group. It is possible that the effect was attenuated because of the lower
SBP in this group with lower signal to noise ratio. Sobieraj et al. exam-
ining the SPRINT database reported that there were adverse effects or a J
curve low on-treatment diastolic blood pressure on cardiovascular risk in
the SPRINT population and that after adjusting for covariates, low dia-
stolic blood pressure showed no significant effects on cardiovascular risk
[19,20,21]. These authors did not report on all-cause mortality.
5. Conclusion
SPRINT participants who required more than one drug to achieve the
same SBP at three months had higher all-cause mortality compared to
those who received only one drug. A statistically significant U curve
relationship between SBP at three months and all-cause mortality was
observed in patients randomized to the standard target group. Those who
were randomized to standard treatment target had a U curve relationship
between SBP at three months and all-cause mortality. The U curves in the
combined group and the intensive treatment group were less
pronounced.
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